



HU000025749T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 025 749**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA(21) Magyar ügyszám: **E 05 855956**(22) A bejelentés napja: **2005. 12. 30.**

(96) Az európai bejelentés bejelentési száma:

EP 20050855956

(97) Az európai bejelentés közzétételi adatai:

EP 1830876 A2 **2006. 07. 06.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 1830876 B1 **2015. 04. 08.**(51) Int. Cl.: **A61K 3147/45** (2006.01)**A61K 314/09** (2006.01)**A61K 39/00** (2006.01)**A61P 35/04** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

PCT/US 05/047467

(87) A nemzetközi közzétételi szám:

WO 06071997

(30) Elsőbbségi adatok:

640491 P **2004. 12. 30.** **US**

(72) Feltaláló(k):

BENNINGHOFF, Bernd, 91349 Egloffstein-Affalterthal
(DE)**HENGGE, Ulrich, R, 45219 Essen (DE)**

(73) Jogosult(ak):

Meda AB, 170 09 Solna (SE)

(74) Képviselő:

dr. Török Ferenc, DANUBIA Szabadalmi és
Jogi Iroda Kft., Budapest

(54)

Imiquimod alkalmazása emlőrákból származó, bőrben jelentkező metasztázisok kezelésére

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 1 830 876 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
08.04.2015 Bulletin 2015/15

(51) Int Cl.:
A61K 31/4745 (2006.01) **A61K 31/409** (2006.01)
A61K 39/00 (2006.01) **A61P 35/04** (2006.01)

(21) Application number: **05855956.8**

(86) International application number:
PCT/US2005/047467

(22) Date of filing: **30.12.2005**

(87) International publication number:
WO 2006/071997 (06.07.2006 Gazette 2006/27)

(54) **USE OF IMIQUIMOD FOR THE TREATMENT OF CUTANEOUS METASTASES DERIVED FROM A BREAST CANCER TUMOR**

VERWENDUNG VON IMIQUIMOD FÜR DIE BEHANDLUNG VON HAUTMETASTASEN STAMMEND
AUS EINEM BRUSTKREBS

UTILISATION DE L'IMIQUIMOD POUR LE TRAITEMENT DE METASTASES CUTANÉES DÉRIVÉES
D'UNE TUMEUR DU CANCER DU SEIN

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **30.12.2004 US 640491 P**

(43) Date of publication of application:
12.09.2007 Bulletin 2007/37

(60) Divisional application:
11180038.9 / 2 394 650

(73) Proprietor: **Meda AB**
170 09 Solna (SE)

(72) Inventors:
• **BENNINGHOFF, Bernd**
91349 Egloffstein-Affalterthal (DE)
• **HENGGE, Ulrich, R**
45219 Essen (DE)

(74) Representative: **Vossius & Partner**
Siebertstrasse 3
81675 München (DE)

(56) References cited:
US-A1- 2003 072 760 US-A1- 2004 076 633
US-A1- 2005 119 273 US-B2- 6 894 060
US-B2- 7 125 836

- **UGUREL S ET AL:** "Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread." September 2002 (2002-09), THE BRITISH JOURNAL OF DERMATOLOGY SEP 2002, VOL. 147, NR. 3, PAGE(S) 621 - 624 , XP002521150 ISSN: 0007-0963 * the whole document *
- **WOLF INGRID H ET AL:** "Locoregional cutaneous metastases of malignant melanoma and their management." DERMATOLOGIC SURGERY : OFFICIAL PUBLICATION FOR AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY [ET AL.] FEB 2004, vol. 30, no. 2 Pt 2, February 2004 (2004-02), pages 244-247, XP002521146 ISSN: 1076-0512
- **HESLING C ET AL:** "In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases." THE BRITISH JOURNAL OF DERMATOLOGY APR 2004, vol. 150, no. 4, April 2004 (2004-04), pages 761-767, XP002521147 ISSN: 0007-0963
- **SCHÖN MICHAEL P ET AL:** "Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod." THE JOURNAL OF INVESTIGATIVE DERMATOLOGY MAY 2004, vol. 122, no. 5, May 2004 (2004-05), pages 1266-1276, XP002521148 ISSN: 0022-202X

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 830 876 B1

- | | |
|--|---|
| <ul style="list-style-type: none">• DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2002 (2002-09), MOORE SUSAN: "Cutaneous metastatic breast cancer." XP002521151 Database accession no. NLM12240484 & CLINICAL JOURNAL OF ONCOLOGY NURSING 2002 SEP-OCT, vol. 6, no. 5, September 2002 (2002-09), pages 255-260, ISSN: 1092-1095• SCHWARTZ ROBERT A ET AL: "Secondary mucinous carcinoma of the skin: metastatic breast cancer." DERMATOLOGIC SURGERY : OFFICIAL PUBLICATION FOR AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY [ET AL.] FEB 2004, vol. 30, no. 2 Pt 1, February 2004 (2004-02), pages 234-235, XP002521149 ISSN: 1076-0512 | <ul style="list-style-type: none">• DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2003 (2003-02), KRATHEN RICHARD A ET AL: "Cutaneous metastasis: a meta-analysis of data." XP002521152 Database accession no. NLM12630642 & SOUTHERN MEDICAL JOURNAL FEB 2003, vol. 96, no. 2, February 2003 (2003-02), pages 164-167, ISSN: 0038-4348 |
|--|---|

Description

[0001] The present invention relates to the use of the IRM compound 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine in the manufacture of a medicament effective for treating cutaneous metastases.

Background

[0002] Cutaneous metastases are secondary tumors associated with many different types of cancer. They occur when cancerous cells break away from a primary tumor and become established as secondary tumors. Metastatic tumors often cause accelerated deterioration of the patient's condition and, therefore, can be fatal. Cutaneous metastases occur as a result of one or more metastatic processes that can include, for example, primary tumor proliferation, local extension, vascular and/or lymphatic penetration and embolization, accidental transfer of malignant cells during diagnostic or surgical procedures, and release of malignant cells.

[0003] Cutaneous metastases occur in up to about 9% of all cancer patients, but occur most frequently in connection with breast cancer in women and in connection with lung cancer in men. Melanoma, ovarian, oral cavity, renal, colon, and gastric primary cancers account for about 90% of all cutaneous metastases.

[0004] Patients typically present with rapidly developing nodules or tumors, often on chest, scalp, neck, abdomen, or back. Less frequent sites include the upper extremities and the pelvis. Patients may report pain, tenderness, and/or infection. Cutaneous metastases are characterized by tumor invasion with capillary rupture, necrosis, and infection, which can result in a purulent, friable, and malodorous lesion. Cutaneous metastases may show characteristics of the primary tumor. In other cases, however, cells of the metastatic tumor may become at least partially undifferentiated.

[0005] Treatment of cutaneous metastases depends, at least in part, on the treatment of the primary tumor. Often, this can include systemic therapy, but can also include local treatments including, for example, surgical excision, irradiation, chemotherapy, cryotherapy, laser therapy, or hormone therapy. The side effects of many such treatments are well characterized.

[0006] Social isolation, embarrassment, even ostracism can result from disfigurement and/or odor associated with cutaneous metastases. Therefore, effective treatment of cutaneous metastases can significantly enhance a patient's quality of life and may even prolong a patient's life. There is an existing need to find additional effective treatments for cutaneous metastases that result in fewer or less severe side effects and may prolong life.

[0007] Topical use of imiquimod for treating cutaneous metastases from melanoma is discussed, for example, in Ugurel S. et al., "Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread", British Journal of Der-

matology 2002, vol. 147, no. 3, pages 621 - 624;

Wolf Ingrid H. et al.: "Locoregional cutaneous metastases of malignant melanoma and their management", Dermatologic Surgery 2004: Official Publication by the American Society for Dermatologic Surgery, Inc., vol. 30:2, Part 2, February 2004, pages 244-247;

Hesling C. et al.: "In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases", British Journal of Dermatology 2004, vol. 150, no. 4, pages 761-767; and

Schon Michael P. et al.: "Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, MAY 2004, vol. 122, no. 5, pages 1266-1276. Treatment of (metastatic) breast cancer is discussed, for example, in DATABASE MEDLINE [Online] US National Library of Medicine (NLM), BETHESDA, MD, US; September 2002, Moore Susan: "Cutaneous metastatic breast cancer", Database accession no. NLM12240484 & Clinical Journal of Oncology Nursing, 2002 Sep-Oct, vol. 6, no. 5, pages 255-260;

Schwartz Robert A. et al.: "Secondary mucinous carcinoma of the skin: metastatic breast cancer", Dermatologic Surgery 2004: Official Publication by the American Society for Dermatologic Surgery, Inc., vol. 30:2, February 2004, pages 234-235; and

DATABASE MEDLINE [Online] US National Library of Medicine (NLM), BETHESDA, MD, US; February 2003, Krathen Richard A. et al.: "Cutaneous metastasis: a meta-analysis of data", Database accession no. NLM12630642 & Southern Medical Journal, Feb 2003, vol. 96, no. 2, pages 164-167.

Summary

[0008] The present invention relates to the use of the IRM compound 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine in the manufacture of a medicament effective for treating cutaneous metastases, wherein the cutaneous metastasis is derived from a breast cancer tumor, as described in the claims.

[0009] It has been found that certain small molecule IRMs can be used to treat cutaneous metastases. Accordingly, the present description describes a method of treating a cutaneous metastasis in a patient in need of such treatment. Generally, the method includes identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering an IRM compound to the treatment area in an amount effective for treating the lesion.

[0010] The present description also describes a method of treating a cutaneous metastasis in a patient in need of such treatment. Generally, the method includes identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering a TLR7 agonist to the treatment area in an amount effective

for treating the lesion.

[0011] The present description also describes a method of treating a cutaneous metastasis in a patient in need of such treatment. Generally, the method includes identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering a TLR8 agonist to the treatment area in an amount effective for treating the lesion.

[0012] Various other features and advantages of the present invention should become readily apparent with reference to the following detailed description, examples, claims and appended drawings. In several places throughout the specification, guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

Brief Description of the Drawings

[0013]

Fig. 1A shows an irregular inflammatory erythema on the left shoulder of a patient.

Fig. 1B shows histological examination of a biopsy taken from the irregular inflammatory erythema shown in Fig. 1A.

Fig. 1C shows immunohistological examination of a biopsy taken from the irregular inflammatory erythema shown in Fig. 1A.

Fig. 1D shows immunohistological examination of a biopsy taken from the irregular inflammatory erythema shown in Fig. 1A.

Fig. 1E shows immunohistological examination of a biopsy taken from the irregular inflammatory erythema shown in Fig. 1A.

Fig. 1F shows the area of the irregular inflammatory erythema shown in Fig. 1A after treatment with an IRM compound.

Fig. 1G shows histological examination of the area after treatment with an IRM compound.

Fig. 1H shows immunohistological examination of the area after treatment with an IRM compound.

Fig. 1I shows histological examination of cutaneous metastasis of invasive ductal carcinoma before treatment with an IRM compound.

Fig. 1J shows histological examination of cutaneous metastasis of invasive ductal carcinoma after treatment with an IRM compound.

Detailed Description of Illustrative Embodiments of the Invention

[0014] It has now been found that certain immune response modifier (IRM) compounds may provide effective treatment of cutaneous metastases. Generally, IRM compounds can act by stimulating certain key aspects of the immune system, as well as by suppressing certain other aspects. Certain IRM compounds appear to act

through Toll-like receptors (TLRs) to induce selected cytokine biosynthesis, induction of co-stimulatory molecules, and increased antigen-presenting capacity. Certain compounds (e.g., IRM compounds and/or TLR agonists) can provide effective treatment of cutaneous metastases when topically administered to the area of the skin affected by the cutaneous metastasis. Often, patients affected by cutaneous metastases are undergoing radiation and/or chemotherapy for the primary tumor and may not easily tolerate additional radiation and/or chemotherapy to manage the cutaneous metastasis. Therefore, the present invention provides an alternative treatment for cutaneous metastases that is simple, non-invasive, well tolerated, and effective.

[0015] The cutaneous metastasis may arise from any type of primary cancer such as, for example, breast, lung, melanoma, head and neck, ovarian, oral cavity, renal, colon, or gastric primary cancer. In some embodiments, the primary cancer may be a solid tumor such as, for example, breast cancer or lung cancer. In certain embodiments, the primary cancer is a Her2/neu-positive breast cancer. In other embodiments, the primary cancer is a Her2/neu-negative breast cancer.

[0016] The cutaneous metastasis may be an intradermal metastasis, i.e., a secondary tumor located between the layers of the skin. Moreover, the metastatic process may involve the lymphatic system, and so may be characterized as a lymphatic metastasis.

[0017] Certain IRMs are small organic molecules (e.g., molecular weight under about 1000 Daltons, preferably under about 500 Daltons, as opposed to large biological molecules such as proteins, peptides, and the like) such as those disclosed in, for example, U.S. Patent Nos. 4,689,338; 4,929,624; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640; 5,446,153; 5,482,936; 5,756,747; 6,110,929; 6,194,425; 6,331,539; 6,376,669; 6,451,810; 6,525,064; 6,541,485; 6,545,016; 6,545,017; 6,573,273; 6,656,938; 6,660,735; 6,660,747; 6,664,260; 6,664,264; 6,664,265; 6,667,312; 6,670,372; 6,677,347; 6,677,348; 6,677,349; 6,683,088; 6,756,382; 6,797,718; and 6,818,650; U.S. Patent Publication Nos. 2004/0091491; 2004/0147543; and 2004/0176367; and International Publication Nos. WO 2005/18551, WO 2005/18556, WO 2005/20999, WO 2005/032484, WO 2005/048933, WO 2005/048945, WO 2005/051317, WO 2005/051324, WO 2005/066169, WO 2005/066170, WO 2005/066172, WO 2005/076783, and WO 2005/079195.

[0018] Additional examples of small molecule IRMs include certain purine derivatives (such as those described in U.S. Patent Nos. 6,376,501, and 6,028,076), certain imidazoquinoline amide derivatives (such as those described in U.S. Patent No. 6,069,149), certain imidazopyridine derivatives (such as those described in U.S. Patent No. 6,518,265), certain benzimidazole derivatives (such as those described in U.S. Patent 6,387,938), certain derivatives of a 4-aminopyrimidine fused to a five membered nitrogen containing heterocyclic ring (such as adenine derivatives described in U. S. Patent Nos.

6,376,501; 6,028,076 and 6,329,381; and in WO 02/08905), certain 3- β -D-ribofuranosylthiazolo[4,5-d]pyrimidine derivatives (such as those described in U.S. Publication No. 2003/0199461), and certain small molecule immuno-potentiator compounds such as those described, for example, in US2005/0136065.

[0019] Other IRMs include large biological molecules such as oligonucleotide sequences. Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Patent Nos. 6,194,388; 6,207,646; 6,239,116; 6,339,068; and 6,406,705. Some CpG-containing oligonucleotides can include synthetic immunomodulatory structural motifs such as those described, for example, in U.S. Patent Nos. 6,426,334 and 6,476,000. Other IRM nucleotide sequences lack CpG sequences and are described, for example, in International Patent Publication No. WO 00/75304. Still other IRM nucleotide sequences include guanosine- and uridine-rich single-stranded RNA (ssRNA) such as those described, for example, in Heil et al., Science, vol. 303, pp. 1526-1529, March 5, 2004.

[0020] Other IRMs include biological molecules such as aminoalkyl glucosaminide phosphates (AGPs) and are described, for example, in U.S. Patent Nos. 6,113,918; 6,303,347; 6,525,028; and 6,649,172.

[0021] Unless otherwise indicated, reference to a compound can include the compound in any pharmaceutically acceptable form, including any isomer (e.g., diastereomer or enantiomer), salt, solvate, polymorph, and the like. In particular, if a compound is optically active, reference to the compound can include each of the compound's enantiomers as well as racemic mixtures of the enantiomers.

[0022] In some embodiments described herein, the IRM compound may be an agonist of at least one Toll-like receptor (TLR) such as, for example, TLR7 or TLR8. The IRM may also in some cases be an agonist of TLR9. In certain embodiments, the IRM compound may be a TLR7 agonist and/or a TLR8 agonist. In certain specific embodiments, the IRM compound may be a TLR7/8 agonist.

[0023] As used herein, "agonist" refers to a compound that can combine with a receptor (e.g., a TLR) to induce a cellular activity. An agonist may be a ligand that directly binds to the receptor. Alternatively, an agonist may combine with a receptor indirectly by, for example, (a) forming a complex with another molecule that directly binds to the receptor, or (b) otherwise results in the modification of another compound so that the other compound directly binds to the receptor. Thus, an agonist may be referred to as an agonist of a particular TLR (e.g., a TLR7-selective agonist) or a particular combination of TLRs (e.g., a TLR 7/8 agonist - an agonist of both TLR7 and TLR8).

[0024] As used herein, the term "TLR7-selective agonist" refers to any compound that acts as an agonist of TLR7, but does not act as an agonist of TLR8. A "TLR8-selective agonist" refers to a compound that acts as an agonist of TLR8, but does not act as an agonist of TLR7.

[0025] A TLR7-selective agonist or a TLR8-selective agonist may act as an agonist for the indicated TLR and one or more of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR9, or TLR10. Accordingly, while "TLR7-selective agonist" may refer to a compound that acts as an agonist for TLR7 and for no other TLR, it may alternatively refer to a compound that acts as an agonist of TLR7 and, for example, TLR6. Similarly, "TLR8-selective agonist" may refer to a compound that acts as an agonist for TLR8 and for no other TLR, but it may alternatively refer to a compound that acts as an agonist of TLR8 and, for example, TLR6.

[0026] The TLR agonism for a particular compound may be assessed in any suitable manner. For example, assays and recombinant cell lines suitable for detecting TLR agonism of test compounds are described, for example, in U.S. Patent Publication Nos. US2004/0014779, US2004/0132079, US2004/0162309, US2004/0171086, US2004/0191833, and US2004/0197865.

[0027] Regardless of the particular assay employed, a compound can be identified as an agonist of a particular TLR if performing the assay with a compound results in at least a threshold increase of some biological activity mediated by the particular TLR. Conversely, a compound may be identified as not acting as an agonist of a specified TLR if, when used to perform an assay designed to detect biological activity mediated by the specified TLR, the compound fails to elicit a threshold increase in the biological activity. Unless otherwise indicated, an increase in biological activity refers to an increase in the same biological activity over that observed in an appropriate control. An assay may or may not be performed in conjunction with the appropriate control. With experience, one skilled in the art may develop sufficient familiarity with a particular assay (e.g., the range of values observed in an appropriate control under specific assay conditions) that performing a control may not always be necessary to determine the TLR agonism of a compound in a particular assay.

[0028] The precise threshold increase of TLR-mediated biological activity for determining whether a particular compound is or is not an agonist of a particular TLR in a given assay may vary according to factors known in the art including but not limited to the biological activity observed as the endpoint of the assay, the method used to measure or detect the endpoint of the assay, the signal-to-noise ratio of the assay, the precision of the assay, and whether the same assay is being used to determine the agonism of a compound for two or more TLRs. Accordingly it is not practical to set forth generally the threshold increase of TLR-mediated biological activity required to identify a compound as being an agonist or a non-agonist of a particular TLR for all possible assays. Those of ordinary skill in the art, however, can readily determine the appropriate threshold with due consideration of such factors.

[0029] Assays employing HEK293 cells transfected

with an expressible TLR structural gene may use a threshold of, for example, at least a three-fold increase in a TLR-mediated biological activity (e.g., NF κ B activation) when the compound is provided at a concentration of, for example, from about 1 μ M to about 10 μ M for identifying a compound as an agonist of the TLR transfected into the cell. However, different thresholds and/or different concentration ranges may be suitable in certain circumstances. Also, different thresholds may be appropriate for different assays.

[0030] In some embodiments described herein, the IRM compound may be a small molecule immune response modifier (e.g., molecular weight of less than about 1000 Daltons).

[0031] In some embodiments described herein, the IRM compound may include a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring, or a 4-aminopyrimidine fused to a five membered nitrogen-containing heterocyclic ring.

[0032] IRM compounds suitable for use described herein include compounds having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring. Such compounds include, for example, imidazoquinoline amines including but not limited to substituted imidazoquinoline amines such as, for example, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, hydroxylamine substituted imidazoquinoline amines, oxime substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl, heteroaryl, aryloxy or arylalkyleneoxy substituted imidazoquinoline amines, and imidazoquinoline diamines; tetrahydroimidazoquinoline amines including but not limited to amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, thioether substituted tetrahydroimidazoquinoline amines, hydroxylamine substituted tetrahydroimidazoquinoline amines, oxime substituted tetrahydroimidazoquinoline amines, and tetrahydroimidazoquinoline diamines; imidazopyridine amines including but not limited to amide substituted imidazopyridine amines, sulfonamide substituted imidazopyridine amines, urea substituted imidazopyridine amines, aryl ether substituted imidazopyridine amines, heterocyclic ether substituted imidazopyridine amines, amido ether substituted imidazopyridine amines, sulfonamido ether substituted imidazopyridine amines, urea

substituted imidazopyridine ethers, and thioether substituted imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines; tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines; thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolophthyridine amines; thiazolonaphthyridine amines; pyrazolopyridine amines; pyrazoloquinoline amines; tetrahydropyrazoloquinoline amines; pyrazolonaphthyridine amines; tetrahydropyrazolonaphthyridine amines; and 1*H*-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines.

[0033] In certain embodiments, the IRM compound may be an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolophthyridine amine, a thiazolonaphthyridine amine, a pyrazolopyridine amine, a pyrazoloquinoline amine, a tetrahydropyrazoloquinoline amine, a pyrazolonaphthyridine amine, or a tetrahydropyrazolonaphthyridine amine.

[0034] In one embodiment, the IRM compound may be an imidazoquinoline amine such as, for example, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine or 4-amino- α,α -dimethyl-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol.

[0035] The claimed invention relates to the use of the IRM compound 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

[0036] Suitable IRM compounds also may include the purine derivatives, imidazoquinoline amide derivatives, benzimidazole derivatives, adenine derivatives, aminoalkyl glucosaminide phosphates, and oligonucleotide sequences described above.

[0037] The IRM compound may be provided in any formulation suitable for administration to a subject. Suitable types of formulations are described, for example, in U.S. Pat. No. 5,238,944; U.S. Pat. No. 5,939,090; U.S. Pat. No. 6,245,776; European Patent No. EP 0 394 026; International Patent Publication No. WO 03/045391; International Patent Publication No. WO 05/089317; and U.S. Patent Publication No. 2003/0199538.

[0038] The compound may be provided in any suitable form including but not limited to a solution, a suspension, an emulsion, or any form of mixture. The compound may be delivered in formulation with any pharmaceutically acceptable excipient, carrier, or vehicle. For example, the formulation may be delivered in a conventional topical dosage form such as, for example, a cream, an ointment, an aerosol formulation, a non-aerosol spray, a gel, a lotion, and the like. The formulation may further include one or more additives including but not limited to adjuvants, skin penetration enhancers, colorants, fragrances, moisturizers, thickeners, and the like. In certain embodiments, the formulation may be delivered topically.

[0039] The composition of a formulation suitable for

practicing the use described herein will vary according to factors known in the art including but not limited to the physical and chemical nature of the IRM compound, the nature of the carrier, the intended dosing regimen, the state of the subject's immune system (e.g., suppressed, compromised, stimulated), the nature of the primary tumor, the nature of the metastatic tumor, the method of administering the IRM compound, and the species to which the formulation is being administered. Accordingly, it is not practical to set forth generally the composition of a formulation effective for treating cutaneous metastases for all possible applications. Those of ordinary skill in the art, however, can readily determine an appropriate formulation with due consideration of such factors.

[0040] In some embodiments, the methods described herein include administering IRM to a subject in a formulation of, for example, from about 0.0001 % to about 20% (unless otherwise indicated, all percentages provided herein are weight/weight with respect to the total formulation) to the subject, although in some embodiments the IRM compound may be administered using a formulation that provides IRM compound in a concentration outside of this range. In certain embodiments, the method includes administering to a subject a formulation that includes from about 0.01% to about 5% IRM compound, for example, a formulation that includes about 1 % to about 5% IRM compound.

[0041] In one embodiment, the formulation may be a cream such as that described, for example, in U.S. Patent No. 5,238,944 that includes about 5% 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

[0042] In another embodiment, the formulation may be a gel such as that described, for example, in U.S. Patent No. 5,939,090 that contains from about 0.01% to about 1.0 % 4-amino- α,α -dimethyl-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol. One particular embodiment includes a gel formulation such as that described, for example, in U.S. Patent No. 5,939,090, that contains about 0.02% 4-amino- α,α -dimethyl-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol. Another particular embodiment includes a gel formulation such as that described, for example, in U.S. Patent No. 5,939,090, that contains about 0.06% 4-amino- α,α -dimethyl-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol.

[0043] In another embodiment, the formulation may be a cream such as that described, for example, in International Patent Publication No. WO 05/089317, that contains from about 0.03% to about 0.3% 2-methyl-1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]naphthyridin-4-amine.

[0044] In another embodiment, the formulation may be a cream such as that described, for example, in International Patent Publication No. WO 05/089317, that contains from about 0.01% to about 1.0% *N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide.

[0045] In yet another embodiment, the formulation may be a cream such as that described, for example, in International Patent Publication No. WO 05/089317, that con-

tains from about 0.01% to about 1.0% *N*-[2-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1,1-dimethylethyl]methanesulfonamide.

[0046] An amount of an IRM compound effective for treating a cutaneous metastasis is an amount sufficient to slow the growth or spreading of the metastatic tumor. In some cases, an amount of an IRM compound effective for treating a cutaneous metastasis is an amount effective to reduce the size of the metastatic tumor even, in some cases, to the point of completely clearing the metastatic tumor. The precise amount of IRM compound necessary for treating a cutaneous metastasis will vary according to factors known in the art including but not limited to the physical and chemical nature of the IRM compound, the nature of the carrier, the intended dosing regimen, the state of the subject's immune system (e.g., suppressed, compromised, stimulated), the nature of the primary tumor, the nature of the metastatic tumor, the method of administering the IRM compound, and the species to which the formulation is being administered. Accordingly, it is not practical to set forth generally the amount that constitutes an amount of IRM compound effective for treating cutaneous metastases for all possible applications. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.

[0047] In some embodiments, the methods described herein include administering sufficient IRM compound to provide a dose of, for example, from about 100 ng/kg to about 50 mg/kg to the subject, although in some embodiments the methods may be performed by administering IRM compound in a dose outside this range. In some of these embodiments, the method includes administering sufficient IRM compound to provide a dose of from about 10 μ g/kg to about 5 mg/kg to the subject, for example, a dose of about 100 μ g/kg to about 1 mg/kg.

[0048] The dosing regimen may depend at least in part on many factors known in the art including but not limited to the physical and chemical nature of the IRM compound, the nature of the carrier, the amount of IRM being administered, the state of the subject's immune system (e.g., suppressed, compromised, stimulated), the nature of the primary tumor, the nature of the metastatic tumor, the method of administering the IRM compound, and the species to which the formulation is being administered. Accordingly it is not practical to set forth generally the dosing regimen effective for treating a cutaneous metastasis for all possible applications. Those of ordinary skill in the art, however, can readily determine an appropriate dosing regimen with due consideration of such factors.

[0049] In some embodiments of the invention, the dosing regimen can include administering the IRM compound, for example, from a single dose to about multiple doses per week. In certain embodiments, the IRM compound may be administered from about once per week to about once per day. In one particular embodiment, the IRM compound is administered five times per week.

[0050] In some embodiments, the dosing regimen may

include administering the IRM compound, for example, from a single dose to a period of many months. In some cases, the IRM compound may be administered for a period necessary to resolve or clear the metastatic tumor. Thus, treatment may be terminated upon clearance of the metastatic tumor as determined by any suitable method such as, for example, gross examination, biopsy, or other histological method. In alternative embodiments, the IRM compound may be administered for a predetermined period of from about two weeks to about two years. In some of these embodiments, the IRM compound may be administered from about two months to about twelve months, for example, for about six months.

[0051] The methods described herein may be performed on any suitable subject. Suitable subjects include but are not limited to animals such as but not limited to humans, non-human primates, rodents, dogs, cats, horses, pigs, sheep, goats, or cows.

Examples

[0052] The following examples have been selected merely to further illustrate features, advantages, and other details of the invention. It is to be expressly understood, however, that while the examples serve this purpose, the particular materials and amounts used as well as other conditions and details are not to be construed in a manner that would unduly limit the scope of this invention.

[0053] The IRM compound used in the examples is 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, formulated as a 5% cream available under the tradename ALDARA (3M Co., St. Paul, MN).

Example 1

[0054] A 65-year old woman with breast cancer (UICC stage pT1c, pN1b1, M0, G2, estrogen-positive, progesterone-positive) developed an axillary recurrence and osteolytic metastases (L2-4) despite axillary dissection and neoadjuvant and adjuvant chemotherapy. The recurrent tumor and metastases were treated with radiation. Nine months later, the breast cancer recurred locally (rpT1c, M1, G2, estrogen-negative, progesterone-negative, Her2/neu-positive) and was treated with trastuzumab and percutaneous radiation. An inflammatory erythema occurred on the upper back (Fig. 1A). On histology, invasive lobular tumor cells (keratin-positive, Her2/neu-positive, ICAM-1-positive) were present (Figs 1B-1E).

[0055] 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine was administered topically five times per week for six months. After the treatment period, no skin lesions were detected upon gross examination or histological examination (Figs. 1F-1H). The patient has remained free of cutaneous metastasis for more than ten months.

Example 2

[0056] A 41-year old woman with invasive ductal carcinoma (UICC stage T2, pN1, B2, cM0) that was estrogen-negative, progesterone-negative, and Her2/neu-negative was treated by mastectomy and adjuvant chemotherapy. Intraclavicular and supraclavicular recurrences were treated with γ - and telecobalt radiation, intraarterial and intravenous chemotherapy. A diffuse cutaneous lesion occurred on the scapula that, upon histological examination, contained an infiltrative ductal growth pattern (Fig. 1I).

[0057] 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine was administered topically five times per week for six months. After the treatment period, a skin biopsy of an affected area was free of carcinoma cells (Fig. 1J).

[0058] Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope of this invention. Illustrative embodiments and examples are provided as examples only and are not intended to limit the scope of the present invention. The scope of the invention is limited only by the claims set forth as follows.

Claims

1. The use of the IRM compound 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine in the manufacture of a medicament effective for treating cutaneous metastases, wherein the cutaneous metastasis is derived from a breast cancer tumor.
2. The use of claim 1 wherein the IRM compound is administered topically.
3. The use of claim 1 wherein the IRM compound is administered at least once per week.
4. The use of claim 1 wherein the IRM compound is administered at least five times per week.
5. The use of claim 1 wherein the IRM compound is administered for at least four weeks.
6. The use of claim 1 wherein the IRM compound is administered for at least six months.
7. The use of claim 1 wherein the cutaneous metastasis is derived from a solid tumor.
8. The use of claim 1 wherein the breast cancer tumor is Her2/neu-positive.
9. The use of claim 1 wherein the breast cancer tumor is Her2/neu-negative.

Patentansprüche

1. Verwendung der Immunmodulatorverbindung (Im-

- mune Response Modifier, IRM) 1-(2-Methylpropyl)-1H-imidazo[4,5-c]chinolin-4-amin bei der Herstellung eines in der Behandlung von Hautmetastasen wirksamen Medikaments, wobei die Hautmetastase von einem Brustkrebstumor abstammt.
2. Verwendung nach Anspruch 1, wobei die Immunmodulatorverbindung topisch verabreicht wird.
 3. Verwendung nach Anspruch 1, wobei die Immunmodulatorverbindung mindestens einmal pro Woche verabreicht wird.
 4. Verwendung nach Anspruch 1, wobei die Immunmodulatorverbindung mindestens fünfmal pro Woche verabreicht wird.
 5. Verwendung nach Anspruch 1, wobei die Immunmodulatorverbindung mindestens vier Wochen lang verabreicht wird.
 6. Verwendung nach Anspruch 1, wobei die Immunmodulatorverbindung mindestens sechs Monate lang verabreicht wird.
 7. Verwendung nach Anspruch 1, wobei die Hautmetastase von einem soliden Tumor abstammt.
 8. Verwendung nach Anspruch 1, wobei der Brustkrebstumor Her2/neu-positiv ist.
 9. Verwendung nach Anspruch 1, wobei der Brustkrebstumor Her2/neu-negativ ist.
- 5 10 15 20 25 30 35

Revendications

1. Utilisation du composé modificateur de réponse immunitaire 1-(2-méthylpropyl)-1H-imidazo[4,5-c]quinoline-4-amine dans la fabrication d'un médicament efficace pour traiter des métastases cutanées, dans laquelle la métastase cutanée est dérivée d'une tumeur de cancer du sein.
 2. Utilisation selon la revendication 1, dans laquelle le composé modificateur de réponse immunitaire est administré localement.
 3. Utilisation selon la revendication 1, dans laquelle le composé modificateur de réponse immunitaire est administré au moins une fois par semaine.
 4. Utilisation selon la revendication 1, dans laquelle le composé modificateur de réponse immunitaire est administré au moins cinq fois par semaine.
 5. Utilisation selon la revendication 1, dans laquelle le composé modificateur de réponse immunitaire est
- 40 45 50 55

administré pendant au moins quatre semaines.

6. Utilisation selon la revendication 1, dans laquelle le composé modificateur de réponse immunitaire est administré pendant au moins six mois.
7. Utilisation selon la revendication 1, dans laquelle la métastase cutanée est dérivée d'une tumeur solide.
8. Utilisation selon la revendication 1, dans laquelle la tumeur de cancer du sein est positive à Her2/neu.
9. Utilisation selon la revendication 1, dans laquelle la tumeur de cancer du sein est négative à Her2/neu.



Fig. 1A




Fig. 1B



Fig. 1C




Fig. 1D




Fig. 1E




Fig. 1F




Fig. 1G




Fig. 1H




Fig. 1I




Fig. 1J

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4689338 A [0017]
- US 4929624 A [0017]
- US 5266575 A [0017]
- US 5268376 A [0017]
- US 5346905 A [0017]
- US 5352784 A [0017]
- US 5389640 A [0017]
- US 5446153 A [0017]
- US 5482936 A [0017]
- US 5756747 A [0017]
- US 6110929 A [0017]
- US 6194425 A [0017]
- US 6331539 A [0017]
- US 6376669 A [0017]
- US 6451810 A [0017]
- US 6525064 A [0017]
- US 6541485 A [0017]
- US 6545016 A [0017]
- US 6545017 A [0017]
- US 6573273 A [0017]
- US 6656938 A [0017]
- US 6660735 A [0017]
- US 6660747 A [0017]
- US 6664260 A [0017]
- US 6664264 A [0017]
- US 6664265 A [0017]
- US 6667312 A [0017]
- US 6670372 A [0017]
- US 6677347 A [0017]
- US 6677348 A [0017]
- US 6677349 A [0017]
- US 6683088 A [0017]
- US 6756382 A [0017]
- US 6797718 A [0017]
- US 6818650 A [0017]
- US 20040091491 A [0017]
- US 20040147543 A [0017]
- US 20040176367 A [0017]
- WO 200518551 A [0017]
- WO 200518556 A [0017]
- WO 200520999 A [0017]
- WO 2005032484 A [0017]
- WO 2005048933 A [0017]
- WO 2005048945 A [0017]
- WO 2005051317 A [0017]
- WO 2005051324 A [0017]
- WO 2005066169 A [0017]
- WO 2005066170 A [0017]
- WO 2005066172 A [0017]
- WO 2005076783 A [0017]
- WO 2005079195 A [0017]
- US 6376501 B [0018]
- US 6028076 B [0018]
- US 6069149 A [0018]
- US 6518265 B [0018]
- US 6387938 B [0018]
- US 6329381 B [0018]
- WO 0208905 A [0018]
- US 20030199461 A [0018]
- US 20050136065 A [0018]
- US 6194388 B [0019]
- US 6207646 B [0019]
- US 6239116 B [0019]
- US 6339068 B [0019]
- US 6406705 B [0019]
- US 6426334 B [0019]
- US 6476000 B [0019]
- WO 0075304 A [0019]
- US 6113918 A [0020]
- US 6303347 A [0020]
- US 6525028 A [0020]
- US 6649172 A [0020]
- US 20040014779 A [0026]
- US 20040132079 A [0026]
- US 20040162309 A [0026]
- US 20040171086 A [0026]
- US 20040191833 A [0026]
- US 20040197865 A [0026]
- US 5238944 A [0037] [0041]
- US 5939090 A [0037] [0042]
- US 6245776 B [0037]
- EP 0394026 A [0037]
- WO 03045391 A [0037]
- WO 05089317 A [0037] [0043] [0044] [0045]
- US 20030199538 A [0037]

Non-patent literature cited in the description

- **UGUREL S. et al.** Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. *British Journal of Dermatology*, 2002, vol. 147 (3), 621-624 [0007]
- Locoregional cutaneous metastases of malignant melanoma and their management. **WOLF INGRID H. et al.** *Dermatologic Surgery* 2004. American Society for Dermatologic Surgery, Inc, February 2004, vol. 30, 244-247 [0007]
- **HESLING C. et al.** In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. *British Journal of Dermatology*, 2004, vol. 150 (4), 761-767 [0007]
- **SCHON MICHAEL P. et al.** Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. *THE JOURNAL OF INVESTIGATIVE DERMATOLOGY*, May 2004, vol. 122 (5), 1266-1276 [0007]
- **MOORE SUSAN.** Cutaneous metastatic breast cancer. *Database accession no. NLM12240484 & Clinical Journal of Oncology*, September 2002, vol. 6 (5), 255-260 [0007]
- Secondary mucinous carcinoma of the skin: metastatic breast cancer. **SCHWARTZ ROBERT A. et al.** *Dermatologic Surgery* 2004. American Society for Dermatologic Surgery, Inc, February 2004, vol. 30, 234-235 [0007]
- DATABASE MEDLINE. US National Library of Medicine, February 2003 [0007]
- **KRATHEN RICHARD A. et al.** Cutaneous metastasis: a meta-analysis of data. *Database accession no. NLM12630642 & Southern Medical Journal*, February 2003, vol. 96 (2), 164-167 [0007]
- **HEIL et al.** *Science*, 05 March 2004, vol. 303, 1526-1529 [0019]

Szabadalmi igénypontok

1. Az 1-(2-metilpropil-1H-imidazo[4,5-c]kinolin-4-amin IRM vegyület alkalmazása olyan gyógyszer előállításában, amely bőrben jelentkező metasztázisok kezelésében hatékony, ahol a bőrben keletkező metasztázis emlőrákból származik.
2. Az 1. igénypont szerinti alkalmazás, ahol az IRM vegyületet topikálisan alkalmazzuk.
3. Az 1. igénypont szerinti alkalmazás, ahol az IRM vegyületet hetente legalább egyszer alkalmazzuk.
4. Az 1. igénypont szerinti alkalmazás, ahol az IRM vegyületet hetente legalább ötször alkalmazzuk.
5. Az 1. igénypont szerinti alkalmazás, ahol az IRM vegyületet legalább 4 héten át alkalmazzuk.
6. Az 1. igénypont szerinti alkalmazás, ahol az IRM vegyületet legalább 6 hónapon át alkalmazzuk.
7. Az 1. igénypont szerinti alkalmazás, ahol a bőrben jelentkező metasztázis egy tömör daganatból származik.
8. Az 1. igénypont szerinti alkalmazás, ahol az emlőrák Her2/neu-pozitív.
9. Az 1. igénypont szerinti alkalmazás, ahol az emlőrák Her2/neu-negatív.